

CITATION REPORT

List of articles citing

Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins

DOI: 10.2165/00003088-200544040-00001
Clinical Pharmacokinetics, 2005, 44, 331-47.

Source: <https://exaly.com/paper-pdf/39421275/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
110	RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. 2005 , 8, 381-402		371
109	Quantitative structure-pharmacokinetic/pharmacodynamic relationships. 2006 , 58, 1326-56		68
108	Target-mediated drug disposition and dynamics. 2006 , 72, 1-10		192
107	Alternative antibody FabTfragment PEGylation strategies: combination of strong reducing agents, disruption of the interchain disulphide bond and disulphide engineering. 2007 , 20, 227-34		40
106	Integrated pharmacokinetics and pharmacodynamics in drug development. <i>Clinical Pharmacokinetics</i> , 2007 , 46, 713-37	6.2	48
105	Enhanced efficacy of 7-hydroxy-3-methoxycadalene via glycosylation in in vivo xenograft study. 2007 , 17, 6335-9		16
104	Antibody engineering and modification technologies. 2007 , 24, 201-15		103
103	Isolation of human anti-idiotypic antibodies by phage display for clinical immune response assays. 2007 , 328, 34-44		23
102	Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targeting GPNMB. 2007 , 60, 423-35		70
101	Substantially improved pharmacokinetics of recombinant human butyrylcholinesterase by fusion to human serum albumin. 2008 , 8, 50		49
100	Protein therapeutics: a summary and pharmacological classification. 2008 , 7, 21-39		1314
99	N-glycosylation as novel strategy to improve pharmacokinetic properties of bispecific single-chain diabodies. 2008 , 283, 7804-12		78
98	Evaluation of an immunoassay for human-specific quantitation of therapeutic antibodies in serum samples from non-human primates. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2009 , 49, 1003-8	3.5	33
97	Novel PEG-coated niosomes based on bola-surfactant as drug carriers for 5-fluorouracil. 2009 , 11, 1115-25		73
96	Physiologically-based PK/PD modelling of therapeutic macromolecules. 2009 , 26, 2543-50		30
95	Optimization of the near-infrared fluorescence labeling for in vivo monitoring of a protein drug distribution in animal model. 2009 , 19, 277-84		9
94	Nonlinear pharmacokinetics of therapeutic proteins resulting from receptor mediated endocytosis. 2009 , 36, 239-60		40

93	Pharmacokinetics and dosage adjustment in patients with renal dysfunction. 2009 , 65, 757-73	191
92	Emerging PEGylated drugs. 2009 , 14, 363-80	195
91	Determination of taspoglutide in human and animal plasma using liquid chromatography-tandem mass spectrometry with orthogonal column-switching. 2009 , 81, 3705-13	27
90	Interspecies scaling of therapeutic monoclonal antibodies: initial look. 2009 , 49, 1382-402	106
89	Strategies to extend plasma half-lives of recombinant antibodies. 2009 , 23, 93-109	160
88	Application of quantitative pharmacology in development of therapeutic monoclonal antibodies. 2010 , 12, 592-601	30
87	PEGylation of therapeutic proteins. 2010 , 5, 113-28	540
86	Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy. 2010 , 24, 9-21	305
85	Pharmacokinetics of OpdA, an organophosphorus hydrolase, in the African green monkey. 2010 , 80, 1075-9	18
84	Type I interferon receptor is a primary regulator of target-mediated drug disposition of interferon-beta in mice. 2010 , 334, 327-32	13
83	Certolizumab pegol: a TNF- α antagonist for the treatment of moderate-to-severe Crohn's disease. 2010 , 44, 333-42	14
82	Population pharmacokinetics of therapeutic monoclonal antibodies. <i>Clinical Pharmacokinetics</i> , 2010 , 49, 633-59	6.2 332
81	Biotechnology-Derived Medicines: What are They? A Pharmacological and a Historical Perspective. 2010 , 7, 145-157	4
80	The β -Tozer model of drug distribution and its suitability for drugs with different pharmacokinetic behavior. 2011 , 7, 1233-43	3
79	Polyethylene Glycol in Clinical Application and PEGylated Drugs. 2011 , 451-493	
78	Characterization and Analysis of Biopharmaceutical Proteins. 2011 , 283-359	2
77	Use of unbound volumes of drug distribution in pharmacokinetic calculations. 2011 , 42, 91-8	12
76	Bispecific Antibodies: Developments and Current Perspectives. 2011 , 1-28	3

75	Recent application of analytical methods to phase I and phase II drugs development: a review. 2012 , 26, 283-300		27
74	Agarose surface coating influences intracellular accumulation and enhances payload stability of a nano-delivery system. 2011 , 28, 1520-30		25
73	Analytical characterization of a novel degradation product in a PEGylated recombinant protein. 2011 , 100, 4607-16		4
72	Daedalus: a robust, turnkey platform for rapid production of decigram quantities of active recombinant proteins in human cell lines using novel lentiviral vectors. 2011 , 39, e143		57
71	Reply to In support of the European Union biosimilar framework. 2012 , 30, 748-749		4
70	Half-Life Modulating Strategies An Introduction. 2012 , 1-21		4
69	Development of anti-infectives using phage display: biological agents against bacteria, viruses, and parasites. 2012 , 56, 4569-82		69
68	Novel Biopharmaceuticals. 2013 , 97-137		4
67	Strategies for enhanced peptide and protein delivery. 2013 , 4, 593-614		26
66	Modeling, simulation, and translation framework for the preclinical development of monoclonal antibodies. 2013 , 15, 551-8		14
65	The utility of modeling and simulation approaches to evaluate immunogenicity effect on the therapeutic protein pharmacokinetics. 2013 , 15, 172-82		26
64	Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects. <i>Clinical Pharmacokinetics</i> , 2013 , 52, 783-92	6.2	251
63	Protein engineering for cardiovascular therapeutics: untapped potential for cardiac repair. 2013 , 113, 933-43		38
62	Method for characterization of PEGylated bioproducts in biological matrixes. 2013 , 85, 9630-7		10
61	Characterization of murine anti-human Fab antibodies for use in an immunoassay for generic quantification of human Fab fragments in non-human serum samples including cynomolgus monkey samples. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2013 , 72, 208-15	3.5	21
60	PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers. 2013 , 19, 11-20		81
59	Rational development and utilization of antibody-based therapeutic proteins in pediatrics. 2013 , 137, 225-47		45
58	Impact of physicochemical properties on pharmacokinetics of protein therapeutics. 2013 , 38, 231-9		8

57	Efficient delivery of p53 and cytochrome c by supramolecular assembly of a dendritic multi-domain delivery system. 2013 , 2, 1620-9	18
56	Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies. 2013 , 5, 576-86	82
55	Chemical and Genetic Modification. 2013 , 1-52	2
54	Application of Mechanistic Pharmacokinetic/Pharmacodynamic Modeling toward the Development of Biologics. 2015 , 109-134	1
53	Biomass Derived and Biomass Inspired Polymers in Pharmaceutical Applications. 2015 , 127-203	5
52	The Molecular Engineering of an Anti-Idiotypic Antibody for Pharmacokinetic Analysis of a Fully Human Anti-Infective. 2015 , 10, e0145381	6
51	Isolation of high-affinity, neutralizing anti-idiotypic antibodies by phage and ribosome display for application in immunogenicity and pharmacokinetic analyses. 2015 , 416, 49-58	13
50	Non-Clinical Pharmacokinetics, Prediction of Human Pharmacokinetics and First-in-Human Dose Selection for CNTO 5825, an Anti-Interleukin-13 Monoclonal Antibody. 2015 , 117, 219-25	10
49	Intracellular transduction of TAT-Hsp27 fusion protein enhancing cell survival and regeneration capacity of cardiac stem cells in acute myocardial infarction. 2015 , 215, 55-72	7
48	Multivalent Conjugates of Sonic Hedgehog Accelerate Diabetic Wound Healing. 2015 , 21, 2366-78	14
47	Intratympanic Gene Delivery of Antimicrobial Molecules in Otitis Media. 2015 , 15, 14	4
46	Therapeutic potential of adenovirus-mediated delivery of Edefensin 2 for experimental otitis media. 2015 , 21, 215-24	14
45	Towards the development of an enzyme replacement therapy for the metabolic disorder propionic acidemia. 2016 , 8, 51-60	6
44	Zwitterionic polymer-protein conjugates reduce polymer-specific antibody response. 2016 , 11, 285-291	65
43	Improvement of in vitro stability and pharmacokinetics of hIFN- β by fusing the carboxyl-terminal peptide of hCG β subunit. 2016 , 221, 13-24	12
42	Biodistribution, pharmacokinetics and toxicity of a <i>Vasconcellea cundinamarcensis</i> proteinase fraction with pharmacological activity. 2016 , 26, 94-101	3
41	Potential Sources of Inter-Subject Variability in Monoclonal Antibody Pharmacokinetics. <i>Clinical Pharmacokinetics</i> , 2016 , 55, 789-805	6.2 37
40	Establishment of a fluorescence-based method to evaluate endocytosis of desialylated glycoproteins in vitro. 2017 , 88, 87-94	1

39	A phase 1, open label, dose escalation study to investigate the safety, tolerability, and pharmacokinetics of MG1102 (apolipoprotein(a) Kringle V) in patients with solid tumors. 2017 , 35, 773-781	4
38	Pharmacological advances for treatment in Duchenne muscular dystrophy. 2017 , 34, 36-48	95
37	Glycosylation and antiproliferative activity of hyperglycosylated IFN- α potentiate HEK293 cells as biofactories. 2017 , 112, 119-131	10
36	Optimal Affinity of a Monoclonal Antibody: Guiding Principles Using Mechanistic Modeling. 2017 , 19, 510-519	11
35	Lipid Carriers: Role and Applications in Nano Drug Delivery. 2017 , 253-289	3
34	Protein Therapeutic: Production, Application, and Future Scenario. 2017 , 73-88	2
33	High yield process for the production of active human β -galactosidase a in CHO-K1 cells through lentivirus transgenesis. 2017 , 33, 1334-1345	3
32	Biopolymer Molecular Weight Can Modulate the Wound Healing Efficacy of Multivalent Sonic Hedgehog-Hyaluronic Acid Conjugates. 2017 , 18, 2350-2359	5
31	Cyanobacterium-Derived Extracellular Carbohydrate Polymer for the Controlled Delivery of Functional Proteins. 2017 , 17, 1600206	15
30	Clinical Pharmacology Review of Plasma-derived and Recombinant Protein Products: CBER Experience and Perspectives on Model-Informed Drug Development. 2019 , 25, e240-e246	7
29	Role of Glycosylation in Modulating Therapeutic Efficiency of Protein Pharmaceuticals. 2019 , 131-143	
28	Monoclonal Antibodies: From Structure to Therapeutic Application. 2019 , 151-190	
27	Strategies for the production of long-acting therapeutics and efficient drug delivery for cancer treatment. 2019 , 113, 108750	46
26	A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody. 2019 , 39, 1284-1297	36
25	Lipo-PEG-PEI complex as an intracellular transporter for protein therapeutics. <i>International Journal of Nanomedicine</i> , 2019 , 14, 1119-1130	7-3 4
24	Integrated Multi-stakeholder Systems Thinking Strategy: Decision-making with Biopharmaceutics Risk Assessment Roadmap (BioRAM) to Optimize Clinical Performance of Drug Products. 2020 , 22, 97	3
23	Considerations for pharmacokinetic assessment of immunoglobulins: Gammagard in very low birth weight neonates with and without baseline-correction. 2020 , 82, 106358	0
22	Model-Based Evaluation of Linear Limited and Bayesian Sparse Sampling for Therapeutic Monitoring of Recombinant Coagulation Factor IX. 2020 , 60, 1453-1460	

21	Population pharmacokinetics of immunoglobulin intravenous preparation in very low birth weight neonates. 2020 , 80, 106192		2
20	More comprehensive standards for monitoring glycosylation. 2021 , 612, 113896		0
19	Bifunctional GM-CSF-derived peptides as tools for O-glycoengineering and protein tagging. 2021 , 327, 18-27		3
18	Clinical Pharmacology of Antibody-Drug Conjugates. <i>Antibodies</i> , 2021 , 10,	7	2
17	Challenges and advancements in the pharmacokinetic enhancement of therapeutic proteins. 2021 , 51, 519-529		3
16	Glycans Associated with Therapeutic Proteins. 2021 , 89-109		
15	Molecular Variants Characterization in Protein Therapeutics Development. 2013 , 207-277		2
14	Monoclonal Antibodies: From Structure to Therapeutic Application. 2013 , 143-178		2
13	Production of Therapeutic Enzymes by Lentivirus Transgenesis. 2019 , 1148, 25-54		2
12	[Clinical pharmacologic principles of the development and application of follow-on biological medicinal products]. 2007 , 148, 915-21		1
11	Brain Cancer Drug Discovery: Clinical Trials, Drug Classes, Targets, and Combinatorial Therapies. 2021 , 73, 1-32		2
10	Introduction to Antibody-Drug Conjugates. <i>Antibodies</i> , 2021 , 10,	7	5
9	Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. <i>International Journal of Nanomedicine</i> , 2006 , 1, 297-315	7.3	658
8	ADME of Biologicals and New Therapeutic Modalities. 2021 ,		
7	Targeted Delivery Methods for Anticancer Drugs.. <i>Cancers</i> , 2022 , 14,	6.6	2
6	Incorporating protein precipitation to resolve hybrid IP-LC-MS assay interference for ultrasensitive quantification of intact therapeutic insulin dimer in human plasma.. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2022 , 212, 114639	3.5	
5	GANAB and N-Glycans Substrates Are Relevant in Human Physiology, Polycystic Pathology and Multiple Sclerosis: A Review. <i>International Journal of Molecular Sciences</i> , 2022 , 23, 7373	6.3	
4	Overview of the Development of Biotherapeutics and the Role of Bioanalytical Sciences. 2022 , 1-22		

- 3 Novel synergistic approaches of protein delivery through physical enhancement for transdermal microneedle drug delivery: A review. **2023**, 84, 104467
- 2 Pharmacokinetics of antibodies during pregnancy: General pharmacokinetics and pregnancy related physiological changes (Part 1). **2023**, 117, 109914
- 1 Amphiphilic Cell-Penetrating Peptides Containing Arginine and Hydrophobic Residues as Protein Delivery Agents. **2023**, 16, 469